Event Abstract

Preparation of hydrophilic C60(OH)10/2-hydroxypropyl-beta-cyclodextrin nanoparticles for the treatment of liver injury induced by oxidative stress

  • 1 Sojo Univeristy, Faculty of Pharmaceutical Sciences, Japan

Introduction: C60(OH)10 is a C60 derivative that 10 hydroxyl groups are introduced into a C60 molecule. It has been reported that polyhydroxylated C60 has a powerful antioxidant activity compared to unmodified C60. Although C60(OH)10 is more soluble than unmodified C60, further enhancement in its solubility is necessary for a precise evaluation of their biological activities and for extensive biomedical applications. In a previous study, we reported on the preparation of stable C60 nanoparticles (mean particle size ca. 90 nm), the surfaces of which were covered by hydrophilic 2-hydroxypropyl-β-cyclodextrin (HP-β-CyD) through physical adsorption and weak hydrophobic interaction. In this study, we prepared the stable hydrophilic C60(OH)10 nanoparticles using HP-β-CyD, and investigated the therapeutic effect of C60(OH)10 nanoparticles as an antioxidant on the acetaminophen (APAP) overdose-induced liver injury.

Materials and Method: C60(OH)10/HP-β-CyD nanoparticles were prepared by grinding the mixture of C60(OH)10 and HP-β-CyD (mainly 1:3 molar ratio) for 3h at 4ºC under reduced pressure. The resulting nanoparticles were characterized by means of a dynamic light scattering machine (DLS), a z-potential analyzer and TEM. The antioxidant ability of C60(OH)10/HP-β-CyD nanoparticles was evaluated by the scavenging ability against DPPH, ABTS and hydroxyl radicals. C60(OH)10/HP-β-CyD nanoparticles were applied to the treatment of an APAP overdose-induced liver injury. Serum ALT and AST levels were monitored in order to measure the level of the liver injury.

Results and Discussion: C60(OH)10/HP-β-CyD nanoparticles showed a small particle size, ca. 50 nm, and maintained this size over 28 days in water at 25˚C. C60(OH)10/HP-β-CyD nanoparticles scavenged DPPH, ABTS and hydroxyl radicals in a dose dependent manner. When C60(OH)10/HP-β-CyD nanoparticles were intravenously administered to mice with a liver injury induced by an overdose of APAP, the ALT and AST levels were markedly reduced to almost the same level as that of normal mice. These results clearly indicate that C60(OH)10/HP-β-CyD nanoparticles have a protective effect against the progression of the liver injury. To reveal the mechanism responsible for liver protection by C60(OH)10/HP-β-CyD nanoparticles, GSH level, CYP2E1 expression and peroxynitrite formation in the liver were assessed. C60(OH)10/HP-β-CyD nanoparticles had no effect on CYP2E1 expression and GSH depletion, but suppressed the generation of peroxynitrite in the liver.

Conclusion: The findings indicate that C60(OH)10/HP-β-CyD nanoparticles protect the liver by suppression of oxidative stress occurred in mitochondria, scavenging ROS such as O2•-, NO and peroxynitrite, which act as critical mediators in the liver injuries.

References:
[1] Iohara et al., Biomaterials, 45, 115-123 (2015).

Keywords: Drug delivery, nanoparticle, Bioactive molecule

Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016.

Presentation Type: Poster

Topic: Biomaterials for therapeutic delivery

Citation: Iohara D, Umezaki Y, Anraku M, Uekama K and Hirayama F (2016). Preparation of hydrophilic C60(OH)10/2-hydroxypropyl-beta-cyclodextrin nanoparticles for the treatment of liver injury induced by oxidative stress. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.01937

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 27 Mar 2016; Published Online: 30 Mar 2016.